Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

被引：0
|
作者：
Langabeer, Stephen E. [1 ]
McCarron, Sarah L. [1 ]
Haslam, Karl [1 ]
Preston, Lisa [1 ]
机构：
[1] St James Hosp, Canc Mol Diagnost, Dublin 8, Ireland
来源：
CLINICAL LABORATORY | 2016年 / 62卷 / 05期
关键词：
chronic myeloid leukemia; tyrosine kinase inhibitors; BCR-ABL1 kinase domain mutations; EUROPEAN LEUKEMIANET; CHRONIC PHASE; RECOMMENDATIONS; INHIBITORS; GUIDELINES;
D O I：
10.7754/Clin.Lab.2015.150938
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：975 / 976
页数：2
相关论文
共 50 条
  • [1] Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
    Soverini, Simona
    de Benedittis, Caterina
    Mancini, Manuela
    Martinelli, Giovanni
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S120 - S128
  • [2] STUDY OF MUTATIONS IN THE KINASE DOMAIN OF BCR-ABL1 BY NGS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Stuckey, Ruth
    Florido, Ortega Yanira
    Rodriguez, Lopez Juan Francisco
    Bilbao, Sieyro Cristina
    Gomez, Casares Maria Teresa
    [J]. HAEMATOLOGICA, 2020, 105 : 239 - 239
  • [3] A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
    Lim, Ye Seul
    Jeong, Na-Rae
    Yoo, Sun-Mi
    Kim, Han Wool
    Lee, Song Hee
    Kim, Dong-Wook
    [J]. BLOOD, 2023, 142
  • [4] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
    Erbilgin, Yucel
    Eskazan, Ahmet Emre
    Ng, Ozden Hatirnaz
    Salihoglu, Ayse
    Elverdi, Tugrul
    Firtina, Sinem
    Tasar, Orcun
    Mercan, Sevcan
    Sisko, Sinem
    Khodzhaev, Khusan
    Ongoren, Seniz
    Ar, Muhlis Cem
    Baslar, Zafer
    Soysal, Teoman
    Sayitoglu, Muge
    Ozbek, Ugur
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 200 - 207
  • [5] Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
    Soverini, Simona
    Branford, Susan
    Nicolini, Franck E.
    Talpaz, Moshe
    Deininger, Michael W. N.
    Martinelli, Giovanni
    Mueller, Martin C.
    Radich, Jerald P.
    Shah, Neil P.
    [J]. LEUKEMIA RESEARCH, 2014, 38 (01) : 10 - 20
  • [6] Are we really looking the right way at resistant BCR-ABL1 kinase domain mutations in chronic myeloid leukemia?
    Pricl, S.
    Laurini, E.
    Fermeglia, M.
    Donato, N. J.
    Cardama, A. Q.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : S43 - S43
  • [7] Chronic Myeloid Leukemia: Beyond BCR-ABL1
    Zhou, Ting
    Medeiros, L. Jeffrey
    Hu, Shimin
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 435 - 445
  • [8] Chronic Myeloid Leukemia: Beyond BCR-ABL1
    Ting Zhou
    L. Jeffrey Medeiros
    Shimin Hu
    [J]. Current Hematologic Malignancy Reports, 2018, 13 : 435 - 445
  • [9] Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
    Liu, Jingjing
    Yang, Haiping
    Xu, Xiuwen
    Yi, Shujuan
    Meng, Li
    [J]. ONCOLOGY LETTERS, 2020, 20 (02) : 1071 - 1076
  • [10] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
12345